*For medical professionals reading reference only
1 minute a day, giving you professional "talk" in the tumor circle! (If you need the original text of the document, you can add the editor’s WeChat yxj_oncology to obtain it)
1
Clin Cancer Res: Oncolytic virus therapy improves drug resistance against PD-1 treatment
▎ Clinical problems:
At present, intratumoral oncolytic virus therapy can reshape the tumor microenvironment through proinflammatory responses to overcome the drug resistance of PD(L)-1 monoclonal antibody treatment.
A study from Clin Cancer Res mainly explores the efficacy of ONCOS-102 (onlycolytic adenovirus expressing GM-CSF) and anti-programmed cell death protein 1 (PD-1) in the treatment of drug-resistant melanoma.
▎ Study Protocol:
This study mainly included patients with advanced melanoma who had previously undergone treatment with PD-1 blocker. All patients included in the study received intratumoral ONCOS-102 treatment, and the treatment regimen was divided into 3 doses (3×10 11 viral load) initial intratumoral injection [Part 1 (sequential treatment)] within the first week, or 4 doses of initial intratumoral injection and 8 intensive doses of intratumoral injection every 3 weeks [Part 2 (combination treatment)]. At the same time, starting from the third week, all patients received pembrolizumab (≤8 doses) every 3 weeks. The primary endpoint of the study was the safety of the drug, and also investigated objective response rate (ORR), progression-free survival (PFS), and immunologic activation in repeated biopsies.
▎ Mainly found:
1. A total of 21 patients (part 1, n=9; part 2, n=12) were tolerated for ONCOS-102 combined with pembrolizumab treatment. The severity of most adverse events (AE) was only mild or moderate. Among them, heat stroke (43%), chills (43%) and nausea (28%) were the most common AEs associated with ONCOS-102, and there was no dose-limiting toxicity.
2. solid tumor had ORR of 35%. In 53% of patients, tumor size reduction was observed in ≥1 non-injectable lesions, indicating that combined treatment has systemic effect.
3. In the injected tumor, the study found that the continuous expression of immune-related genes and T cell infiltration were related to the clinical benefits of patients. The persistence and efficacy of the virus in both injected and uninjected lesions support the use of a Part II dosing regimen for treatment in future studies and does not show additional toxicity.
▎ Outlook:
study found that in patients with advanced melanoma who are resistant to PD-1 treatment, not only are they tolerated with ONCOS-102 combined with pembrolizumab treatment very well, but they can also achieve objective relief. At the same time, ONCOS-102 can continue to promote the infiltration of T cells and (still persisted at week 9), especially cytotoxic CD8+ T cells, which in turn promotes clinical benefits of patients. Therefore, this study emphasizes the importance of future in-depth research on the combined treatment of ONCOS-102 and PD-1 blockers.
References:
[1]https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-2046/709574/Pilot-Study-of-ONCOS-102-and-Pembrolizumab
1. Scan the QR code below
"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"htm"h l3 top magazine essence " H5 page
2. Click " Download now
3. Open Doctor's Station Appp Click column
4. Find in clinical medicines " Top magazine essence "
Follow column
Subscribe to the column, read new top magazines every day!
Download Doctor Station Appp, subscribe anytime and anywhere~
This article was first published: Medical World Tumor Channel
Author: Dingchao Jingyao Group
Editor: Sweet
Copyright Statement
This article is original If you need to reprint, please contact the authorization
- End -
*The medical community strives to ensure the accuracy and reliability of the published content when it is approved, but does not make any commitments and guarantees for the timeliness of the published content, as well as the accuracy and completeness of the cited materials (if any), and does not assume any responsibility arising from the outdated, the possible inaccuracy or incompleteness of the cited materials. Please check separately when using this or using it as the basis for decision-making.
